Download PDF
Semin Respir Crit Care Med 2011; 32(1): 032-043
DOI: 10.1055/s-0031-1272867
© Thieme Medical Publishers

Evolving Concepts in Lung Carcinogenesis

Brigitte N. Gomperts1 , 2 , Avrum Spira3 , Pierre P. Massion4 , 5 , Tonya C. Walser1 , Ignacio I. Wistuba6 , John D. Minna7 , Steven M. Dubinett1 , 8
  • 1Department of Medicine, Division of Pulmonary and Critical Care Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California
  • 2Department of Pediatrics, Division of Hematology and Oncology, Mattel Children's Hospital at UCLA, Los Angeles, California
  • 3Department of Medicine, Department of Pathology and Laboratory Medicine, Boston University School of Medicine, Boston, Massachusetts
  • 4Department of Medicine, Department of Cancer Biology, Thoracic Oncology Center, Vanderbilt-Ingram Cancer Center, Nashville, Tennessee
  • 5Division of Pulmonary and Critical Care Medicine, Veterans Affairs Medical Center, Nashville, Tennessee
  • 6Department of Pathology, Department of Thoracic/Head and Neck Medical Oncology, M. D. Anderson Cancer Center, Houston, Texas
  • 7Department of Medicine, Department of Pharmacology, The University of Texas Southwestern Medical Center, Dallas, Texas
  • 8Department of Pathology and Laboratory Medicine, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, California
Further Information

Publication History

Publication Date:
15 April 2011 (online)

    Permissions and Reprints

ABSTRACT

Lung carcinogenesis is a complex, stepwise process that involves the acquisition of genetic mutations and epigenetic changes that alter cellular processes, such as proliferation, differentiation, invasion, and metastasis. Here, we review some of the latest concepts in the pathogenesis of lung cancer and highlight the roles of inflammation, the “field of cancerization,” and lung cancer stem cells in the initiation of the disease. Furthermore, we review how high throughput genomics, transcriptomics, epigenomics, and proteomics are advancing the study of lung carcinogenesis. Finally, we reflect on the potential of current in vitro and in vivo models of lung carcinogenesis to advance the field and on the areas of investigation where major breakthroughs will lead to the identification of novel chemoprevention strategies and therapies for lung cancer.

KEYWORDS

Field of cancerization - inflammation - stem cells - genomics - epigenomics - proteomics

REFERENCES

  • 1 Dakubo G D, Jakupciak J P, Birch-Machin M A, Parr R L. Clinical implications and utility of field cancerization.  Cancer Cell Int. 2007;  7 2
    CrossrefPubMedSearch in Google Scholar
  • 2 Slaughter D P, Southwick H W, Smejkal W. Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin.  Cancer. 1953;  6 (5) 963-968
    CrossrefPubMedSearch in Google Scholar
  • 3 Auerbach O, Hammond E C, Kirman D, Garfinkel L. Effects of cigarette smoking on dogs, II: Pulmonary neoplasms.  Arch Environ Health. 1970;  21 (6) 754-768
    PubMedSearch in Google Scholar
  • 4 Guo M, House M G, Hooker C et al.. Promoter hypermethylation of resected bronchial margins: a field defect of changes?.  Clin Cancer Res. 2004;  10 (15) 5131-5136
    CrossrefPubMedSearch in Google Scholar
  • 5 Franklin W A, Gazdar A F, Haney J et al.. Widely dispersed p53 mutation in respiratory epithelium: a novel mechanism for field carcinogenesis.  J Clin Invest. 1997;  100 (8) 2133-2137
    CrossrefPubMedSearch in Google Scholar
  • 6 Mao L, Lee J S, Kurie J M et al.. Clonal genetic alterations in the lungs of current and former smokers.  J Natl Cancer Inst. 1997;  89 (12) 857-862
    CrossrefPubMedSearch in Google Scholar
  • 7 Steiling K, Ryan J, Brody J S, Spira A. The field of tissue injury in the lung and airway.  Cancer Prev Res (Phila). 2008;  1 (6) 396-403
    CrossrefPubMedSearch in Google Scholar
  • 8 Tang X, Shigematsu H, Bekele B N et al.. EGFR tyrosine kinase domain mutations are detected in histologically normal respiratory epithelium in lung cancer patients.  Cancer Res. 2005;  65 (17) 7568-7572
    PubMedSearch in Google Scholar
  • 9 Wistuba I I, Lam S, Behrens C et al.. Molecular damage in the bronchial epithelium of current and former smokers.  J Natl Cancer Inst. 1997;  89 (18) 1366-1373
    CrossrefPubMedSearch in Google Scholar
  • 10 Nelson M A, Wymer J, Clements Jr N. Detection of K-ras gene mutations in non-neoplastic lung tissue and lung cancers.  Cancer Lett. 1996;  103 (1) 115-121
    CrossrefPubMedSearch in Google Scholar
  • 11 Powell C A, Klares S, O'Connor G, Brody J S. Loss of heterozygosity in epithelial cells obtained by bronchial brushing: clinical utility in lung cancer.  Clin Cancer Res. 1999;  5 (8) 2025-2034
    PubMedSearch in Google Scholar
  • 12 Tang X, Varella-Garcia M, Xavier A C et al.. Epidermal growth factor receptor abnormalities in the pathogenesis and progression of lung adenocarcinomas.  Cancer Prev Res (Phila). 2008;  1 (3) 192-200
    CrossrefPubMedSearch in Google Scholar
  • 13 Hackett N R, Heguy A, Harvey B G et al.. Variability of antioxidant-related gene expression in the airway epithelium of cigarette smokers.  Am J Respir Cell Mol Biol. 2003;  29 (3 Pt 1) 331-343
    CrossrefPubMedSearch in Google Scholar
  • 14 Spira A, Beane J, Shah V et al.. Effects of cigarette smoke on the human airway epithelial cell transcriptome.  Proc Natl Acad Sci U S A. 2004;  101 (27) 10143-10148
    CrossrefPubMedSearch in Google Scholar
  • 15 Spira A, Beane J E, Shah V et al.. Airway epithelial gene expression in the diagnostic evaluation of smokers with suspect lung cancer.  Nat Med. 2007;  13 (3) 361-366
    CrossrefPubMedSearch in Google Scholar
  • 16 Beane J, Sebastiani P, Whitfield T H et al.. A prediction model for lung cancer diagnosis that integrates genomic and clinical features.  Cancer Prev Res (Phila). 2008;  1 (1) 56-64
    CrossrefPubMedSearch in Google Scholar
  • 17 Bhutani M, Pathak A K, Fan Y H et al.. Oral epithelium as a surrogate tissue for assessing smoking-induced molecular alterations in the lungs.  Cancer Prev Res (Phila). 2008;  1 (1) 39-44
    CrossrefPubMedSearch in Google Scholar
  • 18 Sridhar S, Schembri F, Zeskind J et al.. Smoking-induced gene expression changes in the bronchial airway are reflected in nasal and buccal epithelium.  BMC Genomics. 2008;  9 259
    CrossrefPubMedSearch in Google Scholar
  • 19 Miyazu Y M, Miyazawa T, Hiyama K et al.. Telomerase expression in noncancerous bronchial epithelia is a possible marker of early development of lung cancer.  Cancer Res. 2005;  65 (21) 9623-9627
    CrossrefPubMedSearch in Google Scholar
  • 20 Ocak S, Sos M L, Thomas R K, Massion P P. High-throughput molecular analysis in lung cancer: insights into biology and potential clinical applications.  Eur Respir J. 2009;  34 (2) 489-506
    CrossrefPubMedSearch in Google Scholar
  • 21 Esteller M, Fraga M F, Paz M F et al.. Cancer epigenetics and methylation.  Science. 2002;  297 1807-1808 discussion 1807-1808
    PubMedSearch in Google Scholar
  • 22 Ahrendt S A, Chow J T, Xu L H et al.. Molecular detection of tumor cells in bronchoalveolar lavage fluid from patients with early stage lung cancer.  J Natl Cancer Inst. 1999;  91 (4) 332-339
    CrossrefPubMedSearch in Google Scholar
  • 23 Cheng X, Blumenthal R M. Mammalian DNA methyltransferases: a structural perspective.  Structure. 2008;  16 (3) 341-350
    CrossrefPubMedSearch in Google Scholar
  • 24 Métivier R, Gallais R, Tiffoche C et al.. Cyclical DNA methylation of a transcriptionally active promoter.  Nature. 2008;  452 (7183) 45-50
    CrossrefPubMedSearch in Google Scholar
  • 25 Esteller M, Sanchez-Cespedes M, Rosell R, Sidransky D, Baylin S B, Herman J G. Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients.  Cancer Res. 1999;  59 (1) 67-70
    PubMedSearch in Google Scholar
  • 26 Belinsky S A, Palmisano W A, Gilliland F D et al.. Aberrant promoter methylation in bronchial epithelium and sputum from current and former smokers.  Cancer Res. 2002;  62 (8) 2370-2377
    PubMedSearch in Google Scholar
  • 27 Ng C S, Zhang J, Wan S et al.. Tumor p16M is a possible marker of advanced stage in non-small cell lung cancer.  J Surg Oncol. 2002;  79 (2) 101-106
    CrossrefPubMedSearch in Google Scholar
  • 28 Palmisano W A, Divine K K, Saccomanno G et al.. Predicting lung cancer by detecting aberrant promoter methylation in sputum.  Cancer Res. 2000;  60 (21) 5954-5958
    PubMedSearch in Google Scholar
  • 29 Brock M V, Hooker C M, Ota-Machida E et al.. DNA methylation markers and early recurrence in stage I lung cancer.  N Engl J Med. 2008;  358 (11) 1118-1128
    CrossrefPubMedSearch in Google Scholar
  • 30 Zhong S, Fields C R, Su N, Pan Y X, Robertson K D. Pharmacologic inhibition of epigenetic modifications, coupled with gene expression profiling, reveals novel targets of aberrant DNA methylation and histone deacetylation in lung cancer.  Oncogene. 2007;  26 (18) 2621-2634
    CrossrefPubMedSearch in Google Scholar
  • 31 Rauch T A, Zhong X, Wu X et al.. High-resolution mapping of DNA hypermethylation and hypomethylation in lung cancer.  Proc Natl Acad Sci U S A. 2008;  105 (1) 252-257
    CrossrefPubMedSearch in Google Scholar
  • 32 Brena R M, Morrison C, Liyanarachchi S et al.. Aberrant DNA methylation of OLIG1, a novel prognostic factor in non-small cell lung cancer.  PLoS Med. 2007;  4 (3) e108
    CrossrefPubMedSearch in Google Scholar
  • 33 Brehm A, Miska E A, McCance D J, Reid J L, Bannister A J, Kouzarides T. Retinoblastoma protein recruits histone deacetylase to repress transcription.  Nature. 1998;  391 (6667) 597-601
    CrossrefPubMedSearch in Google Scholar
  • 34 Mukhopadhyay N K, Weisberg E, Gilchrist D, Bueno R, Sugarbaker D J, Jaklitsch M T. Effectiveness of trichostatin A as a potential candidate for anticancer therapy in non-small-cell lung cancer.  Ann Thorac Surg. 2006;  81 (3) 1034-1042
    CrossrefPubMedSearch in Google Scholar
  • 35 Kim S M, Kee H J, Eom G H et al.. Characterization of a novel WHSC1-associated SET domain protein with H3K4 and H3K27 methyltransferase activity.  Biochem Biophys Res Commun. 2006;  345 (1) 318-323
    CrossrefPubMedSearch in Google Scholar
  • 36 Loprevite M, Tiseo M, Grossi F et al.. In vitro study of CI-994, a histone deacetylase inhibitor, in non-small cell lung cancer cell lines.  Oncol Res. 2005;  15 (1) 39-48
    PubMedSearch in Google Scholar
  • 37 Kouzarides T. Chromatin modifications and their function.  Cell. 2007;  128 (4) 693-705
    CrossrefPubMedSearch in Google Scholar
  • 38 Ambros V. MicroRNA pathways in flies and worms: growth, death, fat, stress, and timing.  Cell. 2003;  113 (6) 673-676
    CrossrefPubMedSearch in Google Scholar
  • 39 Yanaihara N, Caplen N, Bowman E et al.. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis.  Cancer Cell. 2006;  9 (3) 189-198
    CrossrefPubMedSearch in Google Scholar
  • 40 Takamizawa J, Konishi H, Yanagisawa K et al.. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival.  Cancer Res. 2004;  64 (11) 3753-3756
    CrossrefPubMedSearch in Google Scholar
  • 41 Johnson S M, Grosshans H, Shingara J et al.. RAS is regulated by the let-7 microRNA family.  Cell. 2005;  120 (5) 635-647
    Search in Google Scholar
  • 42 Kumar M S, Erkeland S J, Pester R E et al.. Suppression of non-small cell lung tumor development by the let-7 microRNA family.  Proc Natl Acad Sci U S A. 2008;  105 (10) 3903-3908
    CrossrefPubMedSearch in Google Scholar
  • 43 Trang P, Medina P P, Wiggins J F et al.. Regression of murine lung tumors by the let-7 microRNA.  Oncogene. 2010;  29 (11) 1580-1587
    CrossrefPubMedSearch in Google Scholar
  • 44 Ender C, Krek A, Friedländer M R et al.. A human snoRNA with microRNA-like functions.  Mol Cell. 2008;  32 (4) 519-528
    CrossrefPubMedSearch in Google Scholar
  • 45 Eiring A M, Harb J G, Neviani P et al.. miR-328 functions as an RNA decoy to modulate hnRNP E2 regulation of mRNA translation in leukemic blasts.  Cell. 2010;  140 (5) 652-665
    CrossrefPubMedSearch in Google Scholar
  • 46 Agulló-Ortuño M T, López-Ríos F, Paz-Ares L. Lung cancer genomic signatures.  J Thorac Oncol. 2010;  5 (10) 1673-1691
    CrossrefPubMedSearch in Google Scholar
  • 47 Boland C R, Thibodeau S N, Hamilton S R et al.. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer.  Cancer Res. 1998;  58 (22) 5248-5257
    PubMedSearch in Google Scholar
  • 48 Pinkel D, Segraves R, Sudar D et al.. High resolution analysis of DNA copy number variation using comparative genomic hybridization to microarrays.  Nat Genet. 1998;  20 (2) 207-211
    CrossrefPubMedSearch in Google Scholar
  • 49 Pollack J R, Perou C M, Alizadeh A A et al.. Genome-wide analysis of DNA copy-number changes using cDNA microarrays.  Nat Genet. 1999;  23 (1) 41-46
    PubMedSearch in Google Scholar
  • 50 Ishkanian A S, Malloff C A, Watson S K et al.. A tiling resolution DNA microarray with complete coverage of the human genome.  Nat Genet. 2004;  36 (3) 299-303
    CrossrefPubMedSearch in Google Scholar
  • 51 Imoto I, Yuki Y, Sonoda I et al.. Identification of ZASC1 encoding a Krüppel-like zinc finger protein as a novel target for 3q26 amplification in esophageal squamous cell carcinomas.  Cancer Res. 2003;  63 (18) 5691-5696
    PubMedSearch in Google Scholar
  • 52 Singh B, Gogineni S K, Sacks P G et al.. Molecular cytogenetic characterization of head and neck squamous cell carcinoma and refinement of 3q amplification.  Cancer Res. 2001;  61 (11) 4506-4513
    PubMedSearch in Google Scholar
  • 53 Levin N A, Brzoska P M, Warnock M L, Gray J W, Christman M F. Identification of novel regions of altered DNA copy number in small cell lung tumors.  Genes Chromosomes Cancer. 1995;  13 (3) 175-185
    CrossrefPubMedSearch in Google Scholar
  • 54 Amos C I, Wu X, Broderick P et al.. Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1  Nat Genet. 2008;  40 (5) 616-622
    CrossrefPubMedSearch in Google Scholar
  • 55 Hung R J, McKay J D, Gaborieau V et al.. A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25.  Nature. 2008;  452 (7187) 633-637
    CrossrefPubMedSearch in Google Scholar
  • 56 Thorgeirsson T E, Geller F, Sulem P et al.. A variant associated with nicotine dependence, lung cancer and peripheral arterial disease.  Nature. 2008;  452 (7187) 638-642
    CrossrefPubMedSearch in Google Scholar
  • 57 Gustafson A M, Soldi R, Anderlind C et al.. Airway PI3K pathway activation is an early and reversible event in lung cancer development.  Sci Transl Med. 2010;  2 (26) 26ra25
    CrossrefPubMedSearch in Google Scholar
  • 58 Yanagisawa K, Shyr Y, Xu B J et al.. Proteomic patterns of tumour subsets in non-small-cell lung cancer.  Lancet. 2003;  362 (9382) 433-439
    CrossrefPubMedSearch in Google Scholar
  • 59 Rahman S M, Shyr Y, Yildiz P B et al.. Proteomic patterns of preinvasive bronchial lesions.  Am J Respir Crit Care Med. 2005;  172 (12) 1556-1562
    CrossrefPubMedSearch in Google Scholar
  • 60 Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability.  Carcinogenesis. 2009;  30 (7) 1073-1081
    CrossrefPubMedSearch in Google Scholar
  • 61 Brody J S, Spira A. State of the art: chronic obstructive pulmonary disease, inflammation, and lung cancer.  Proc Am Thorac Soc. 2006;  3 (6) 535-537
    CrossrefPubMedSearch in Google Scholar
  • 62 Smith C J, Perfetti T A, King J A. Perspectives on pulmonary inflammation and lung cancer risk in cigarette smokers.  Inhal Toxicol. 2006;  18 (9) 667-677
    CrossrefPubMedSearch in Google Scholar
  • 63 Dubinett S M, Sharma S, Huang M, Dohadwala M, Pold M, Mao J T. Cyclooxygenase-2 in lung cancer.  Prog Exp Tumor Res. 2003;  37 138-162
    PubMedSearch in Google Scholar
  • 64 Dohadwala M, Batra R K, Luo J et al.. Autocrine/paracrine prostaglandin E2 production by non-small cell lung cancer cells regulates matrix metalloproteinase-2 and CD44 in cyclooxygenase-2-dependent invasion.  J Biol Chem. 2002;  277 (52) 50828-50833
    CrossrefPubMedSearch in Google Scholar
  • 65 Lee J M, Mao J T, Krysan K, Dubinett S M. Significance of cyclooxygenase-2 in prognosis, targeted therapy and chemoprevention of NSCLC.  Future Oncol. 2007;  3 (2) 149-153
    CrossrefPubMedSearch in Google Scholar
  • 66 Khuri F R, Wu H, Lee J J et al.. Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer.  Clin Cancer Res. 2001;  7 (4) 861-867
    PubMedSearch in Google Scholar
  • 67 Tsubochi H, Sato N, Hiyama M et al.. Combined analysis of cyclooxygenase-2 expression with p53 and Ki-67 in nonsmall cell lung cancer.  Ann Thorac Surg. 2006;  82 (4) 1198-1204
    CrossrefPubMedSearch in Google Scholar
  • 68 Kim H S, Youm H R, Lee J S, Min K W, Chung J H, Park C S. Correlation between cyclooxygenase-2 and tumor angiogenesis in non-small cell lung cancer.  Lung Cancer. 2003;  42 (2) 163-170
    CrossrefPubMedSearch in Google Scholar
  • 69 Huang M, Stolina M, Sharma S et al.. Non-small cell lung cancer cyclooxygenase-2-dependent regulation of cytokine balance in lymphocytes and macrophages: up-regulation of interleukin 10 and down-regulation of interleukin 12 production.  Cancer Res. 1998;  58 (6) 1208-1216
    PubMedSearch in Google Scholar
  • 70 Mao J T, Cui X, Reckamp K et al.. Chemoprevention strategies with cyclooxygenase-2 inhibitors for lung cancer.  Clin Lung Cancer. 2005;  7 (1) 30-39
    CrossrefPubMedSearch in Google Scholar
  • 71 Subbaramaiah K, Altorki N, Chung W J, Mestre J R, Sampat A, Dannenberg A J. Inhibition of cyclooxygenase-2 gene expression by p53.  J Biol Chem. 1999;  274 (16) 10911-10915
    CrossrefPubMedSearch in Google Scholar
  • 72 Csiki I, Yanagisawa K, Haruki N et al.. Thioredoxin-1 modulates transcription of cyclooxygenase-2 via hypoxia-inducible factor-1alpha in non-small cell lung cancer.  Cancer Res. 2006;  66 (1) 143-150
    CrossrefPubMedSearch in Google Scholar
  • 73 Cui X, Zhang L, Luo J et al.. Unphosphorylated STAT6 contributes to constitutive cyclooxygenase-2 expression in human non-small cell lung cancer.  Oncogene. 2007;  26 (29) 4253-4260
    CrossrefPubMedSearch in Google Scholar
  • 74 Heuze-Vourc'h N, Zhu L, Krysan K, Batra R K, Sharma S, Dubinett S M. Abnormal interleukin 10Ralpha expression contributes to the maintenance of elevated cyclooxygenase-2 in non-small cell lung cancer cells.  Cancer Res. 2003;  63 (4) 766-770
    PubMedSearch in Google Scholar
  • 75 Krysan K, Merchant F H, Zhu L et al.. COX-2-dependent stabilization of survivin in non-small cell lung cancer.  FASEB J. 2004;  18 (1) 206-208
    PubMedSearch in Google Scholar
  • 76 Põld M, Krysan K, Põld A et al.. Cyclooxygenase-2 modulates the insulin-like growth factor axis in non-small-cell lung cancer.  Cancer Res. 2004;  64 (18) 6549-6555
    CrossrefPubMedSearch in Google Scholar
  • 77 Sharma S, Stolina M, Yang S C et al.. Tumor cyclooxygenase 2-dependent suppression of dendritic cell function.  Clin Cancer Res. 2003;  9 (3) 961-968
    PubMedSearch in Google Scholar
  • 78 Põld M, Zhu L X, Sharma S et al.. Cyclooxygenase-2-dependent expression of angiogenic CXC chemokines ENA-78/CXC Ligand (CXCL) 5 and interleukin-8/CXCL8 in human non-small cell lung cancer.  Cancer Res. 2004;  64 (5) 1853-1860
    CrossrefPubMedSearch in Google Scholar
  • 79 Dohadwala M, Batra R K, Luo J et al.. Autocrine/paracrine prostaglandin E2 production by non-small cell lung cancer cells regulates matrix metalloproteinase-2 and CD44 in cyclooxygenase-2-dependent invasion.  J Biol Chem. 2002;  277 (52) 50828-50833
    CrossrefPubMedSearch in Google Scholar
  • 80 Dohadwala M, Yang S-C, Luo J et al.. Cyclooxygenase-2-dependent regulation of E-cadherin: prostaglandin E(2) induces transcriptional repressors ZEB1 and snail in non-small cell lung cancer.  Cancer Res. 2006;  66 (10) 5338-5345
    CrossrefPubMedSearch in Google Scholar
  • 81 Yang L, Huang Y, Porta R et al.. Host and direct antitumor effects and profound reduction in tumor metastasis with selective EP4 receptor antagonism.  Cancer Res. 2006;  66 (19) 9665-9672
    CrossrefPubMedSearch in Google Scholar
  • 82 Lee J M, Dedhar S, Kalluri R, Thompson E W. The epithelial-mesenchymal transition: new insights in signaling, development, and disease.  J Cell Biol. 2006;  172 (7) 973-981
    CrossrefPubMedSearch in Google Scholar
  • 83 Mani S A, Guo W, Liao M J et al.. The epithelial-mesenchymal transition generates cells with properties of stem cells.  Cell. 2008;  133 (4) 704-715
    CrossrefPubMedSearch in Google Scholar
  • 84 Krysan K, Lee J M, Dohadwala M et al.. Inflammation, epithelial to mesenchymal transition, and epidermal growth factor receptor tyrosine kinase inhibitor resistance.  J Thorac Oncol. 2008;  3 (2) 107-110
    CrossrefPubMedSearch in Google Scholar
  • 85 Gotzmann J, Mikula M, Eger A et al.. Molecular aspects of epithelial cell plasticity: implications for local tumor invasion and metastasis.  Mutat Res. 2004;  566 (1) 9-20
    PubMedSearch in Google Scholar
  • 86 Huber M A, Kraut N, Beug H. Molecular requirements for epithelial-mesenchymal transition during tumor progression.  Curr Opin Cell Biol. 2005;  17 (5) 548-558
    CrossrefPubMedSearch in Google Scholar
  • 87 Radisky D C, LaBarge M A. Epithelial-mesenchymal transition and the stem cell phenotype.  Cell Stem Cell. 2008;  2 (6) 511-512
    CrossrefPubMedSearch in Google Scholar
  • 88 St John M A, Dohadwala M, Luo J et al.. Proinflammatory mediators upregulate snail in head and neck squamous cell carcinoma.  Clin Cancer Res. 2009;  15 (19) 6018-6027
    CrossrefPubMedSearch in Google Scholar
  • 89 Baratelli F, Lin Y, Zhu L et al.. Prostaglandin E2 induces FOXP3 gene expression and T regulatory cell function in human CD4 + T cells.  J Immunol. 2005;  175 (3) 1483-1490
    PubMedSearch in Google Scholar
  • 90 Gavin M A, Rasmussen J P, Fontenot J D et al.. Foxp3-dependent programme of regulatory T-cell differentiation.  Nature. 2007;  445 (7129) 771-775
    CrossrefPubMedSearch in Google Scholar
  • 91 Krysan K, Reckamp K L, Dalwadi H et al.. Prostaglandin E2 activates mitogen-activated protein kinase/Erk pathway signaling and cell proliferation in non-small cell lung cancer cells in an epidermal growth factor receptor-independent manner.  Cancer Res. 2005;  65 (14) 6275-6281
    CrossrefPubMedSearch in Google Scholar
  • 92 Ailles L E, Weissman I L. Cancer stem cells in solid tumors.  Curr Opin Biotechnol. 2007;  18 (5) 460-466
    CrossrefPubMedSearch in Google Scholar
  • 93 Boman B M, Wicha M S. Cancer stem cells: a step toward the cure.  J Clin Oncol. 2008;  26 (17) 2795-2799
    CrossrefPubMedSearch in Google Scholar
  • 94 Clarke M F, Fuller M. Stem cells and cancer: two faces of eve.  Cell. 2006;  124 (6) 1111-1115
    CrossrefPubMedSearch in Google Scholar
  • 95 Huntly B J, Gilliland D G. Cancer biology: summing up cancer stem cells.  Nature. 2005;  435 (7046) 1169-1170
    CrossrefPubMedSearch in Google Scholar
  • 96 McDonald S A, Graham T A, Schier S, Wright N A, Alison M R. Stem cells and solid cancers.  Virchows Arch. 2009;  455 (1) 1-13
    PubMedSearch in Google Scholar
  • 97 Rosen J M, Jordan C T. The increasing complexity of the cancer stem cell paradigm.  Science. 2009;  324 (5935) 1670-1673
    CrossrefPubMedSearch in Google Scholar
  • 98 Visvader J E, Lindeman G J. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions.  Nat Rev Cancer. 2008;  8 (10) 755-768
    CrossrefPubMedSearch in Google Scholar
  • 99 Ward R J, Dirks P B. Cancer stem cells: at the headwaters of tumor development.  Annu Rev Pathol. 2007;  2 175-189
    CrossrefPubMedSearch in Google Scholar
  • 100 Kim C F, Jackson E L, Woolfenden A E et al.. Identification of bronchioalveolar stem cells in normal lung and lung cancer.  Cell. 2005;  121 (6) 823-835
    CrossrefPubMedSearch in Google Scholar
  • 101 Curtis S J, Sinkevicius K W, Li D et al.. Primary tumor genotype is an important determinant in identification of lung cancer propagating cells.  Cell Stem Cell. 2010;  7 (1) 127-133
    CrossrefPubMedSearch in Google Scholar
  • 102 Moreb J S. Aldehyde dehydrogenase as a marker for stem cells.  Curr Stem Cell Res Ther. 2008;  3 (4) 237-246
    CrossrefPubMedSearch in Google Scholar
  • 103 Storms R W, Trujillo A P, Springer J B et al.. Isolation of primitive human hematopoietic progenitors on the basis of aldehyde dehydrogenase activity.  Proc Natl Acad Sci U S A. 1999;  96 (16) 9118-9123
    CrossrefPubMedSearch in Google Scholar
  • 104 Carpentino J E, Hynes M J, Appelman H D et al.. Aldehyde dehydrogenase-expressing colon stem cells contribute to tumorigenesis in the transition from colitis to cancer.  Cancer Res. 2009;  69 (20) 8208-8215
    CrossrefPubMedSearch in Google Scholar
  • 105 Chen Y C, Chen Y W, Hsu H S et al.. Aldehyde dehydrogenase 1 is a putative marker for cancer stem cells in head and neck squamous cancer.  Biochem Biophys Res Commun. 2009;  385 (3) 307-313
    CrossrefPubMedSearch in Google Scholar
  • 106 Huang E H, Hynes M J, Zhang T et al.. Aldehyde dehydrogenase 1 is a marker for normal and malignant human colonic stem cells (SC) and tracks SC overpopulation during colon tumorigenesis.  Cancer Res. 2009;  69 (8) 3382-3389
    CrossrefPubMedSearch in Google Scholar
  • 107 Jiang F, Qiu Q, Khanna A et al.. Aldehyde dehydrogenase 1 is a tumor stem cell-associated marker in lung cancer.  Mol Cancer Res. 2009;  7 (3) 330-338
    CrossrefPubMedSearch in Google Scholar
  • 108 Eramo A, Lotti F, Sette G et al.. Identification and expansion of the tumorigenic lung cancer stem cell population.  Cell Death Differ. 2008;  15 (3) 504-514
    CrossrefPubMedSearch in Google Scholar
  • 109 Salnikov A V, Gladkich J, Moldenhauer G, Volm M, Mattern J, Herr I. CD133 is indicative for a resistance phenotype but does not represent a prognostic marker for survival of non-small cell lung cancer patients.  Int J Cancer. 2010;  126 (4) 950-958
    PubMedSearch in Google Scholar
  • 110 Bertolini G, Roz L, Perego P et al.. Highly tumorigenic lung cancer CD133 + cells display stem-like features and are spared by cisplatin treatment.  Proc Natl Acad Sci U S A. 2009;  106 (38) 16281-16286
    CrossrefPubMedSearch in Google Scholar
  • 111 Li F, Zeng H, Ying K. The combination of stem cell markers CD133 and ABCG2 predicts relapse in stage I non-small cell lung carcinomas.  Med Oncol. 2010;  Aug 18. [Epub ahead of print]
    PubMedSearch in Google Scholar
  • 112 Engelhardt J F, Schlossberg H, Yankaskas J R, Dudus L. Progenitor cells of the adult human airway involved in submucosal gland development.  Development. 1995;  121 (7) 2031-2046
    PubMedSearch in Google Scholar
  • 113 Hong K U, Reynolds S D, Watkins S, Fuchs E, Stripp B R. In vivo differentiation potential of tracheal basal cells: evidence for multipotent and unipotent subpopulations.  Am J Physiol Lung Cell Mol Physiol. 2004;  286 (4) L643-L649
    PubMedSearch in Google Scholar
  • 114 Rock J R, Onaitis M W, Rawlins E L et al.. Basal cells as stem cells of the mouse trachea and human airway epithelium.  Proc Natl Acad Sci U S A. 2009;  106 (31) 12771-12775
    CrossrefPubMedSearch in Google Scholar
  • 115 Schoch K G, Lori A, Burns K A, Eldred T, Olsen J C, Randell S H. A subset of mouse tracheal epithelial basal cells generates large colonies in vitro.  Am J Physiol Lung Cell Mol Physiol. 2004;  286 (4) L631-L642
    PubMedSearch in Google Scholar
  • 116 Ooi A T, Mah V, Nickerson D W et al.. Presence of a putative tumor-initiating progenitor cell population predicts poor prognosis in smokers with non-small cell lung cancer.  Cancer Res. 2010;  70 (16) 6639-6648
    CrossrefPubMedSearch in Google Scholar
  • 117 Sánchez-García I. The crossroads of oncogenesis and metastasis.  N Engl J Med. 2009;  360 (3) 297-299
    CrossrefPubMedSearch in Google Scholar
  • 118 Mani S A, Guo W, Liao M-J et al.. The epithelial-mesenchymal transition generates cells with properties of stem cells.  Cell. 2008;  133 (4) 704-715
    CrossrefPubMedSearch in Google Scholar
  • 119 Yu M, Smolen G A, Zhang J et al.. A developmentally regulated inducer of EMT, LBX1, contributes to breast cancer progression.  Genes Dev. 2009;  23 (15) 1737-1742
    CrossrefPubMedSearch in Google Scholar
  • 120 Wellner U, Schubert J, Burk U C et al.. The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs.  Nat Cell Biol. 2009;  11 (12) 1487-1495
    CrossrefPubMedSearch in Google Scholar
  • 121 Yanagawa J, Walser T C, Zhu L X et al.. Snail promotes CXCR2 ligand-dependent tumor progression in non-small cell lung carcinoma.  Clin Cancer Res. 2009;  15 (22) 6820-6829
    CrossrefPubMedSearch in Google Scholar
  • 122 Walser T C, Yanagawa J, Luo J et al.. Snail-induced and EMT-mediated early lung cancer development: promotion of invasion and expansion of stem cell populations. [abstract] Paper presented at: Proceedings of the Seventh Annual AACR International Conference on Frontiers in Cancer Prevention Research; November 16–19, 2008; Washington, DC
  • 123 Wicha M S, Liu S L, Dontu G. Cancer stem cells: an old idea—a paradigm shift.  Cancer Res. 2006;  66 (4) 1883-1890 discussion 1895-1896
    CrossrefPubMedSearch in Google Scholar
  • 124 Sun S, Schiller J H, Gazdar A F. Lung cancer in never smokers—a different disease.  Nat Rev Cancer. 2007;  7 (10) 778-790
    CrossrefPubMedSearch in Google Scholar
  • 125 Fan X, Matsui W, Khaki L et al.. Notch pathway inhibition depletes stem-like cells and blocks engraftment in embryonal brain tumors.  Cancer Res. 2006;  66 (15) 7445-7452
    CrossrefPubMedSearch in Google Scholar
  • 126 Farnie G, Clarke R B. Mammary stem cells and breast cancer—role of Notch signalling.  Stem Cell Rev. 2007;  3 (2) 169-175
    CrossrefPubMedSearch in Google Scholar
  • 127 Konishi J, Kawaguchi K S, Vo H et al.. Gamma-secretase inhibitor prevents Notch3 activation and reduces proliferation in human lung cancers.  Cancer Res. 2007;  67 (17) 8051-8057
    CrossrefPubMedSearch in Google Scholar
  • 128 Westhoff B, Colaluca I N, D'Ario G et al.. Alterations of the Notch pathway in lung cancer.  Proc Natl Acad Sci U S A. 2009;  106 (52) 22293-22298
    CrossrefPubMedSearch in Google Scholar
  • 129 Meuwissen R, Berns A. Mouse models for human lung cancer.  Genes Dev. 2005;  19 (6) 643-664
    CrossrefPubMedSearch in Google Scholar
  • 130 Olive K P, Tuveson D A, Ruhe Z C et al.. Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome.  Cell. 2004;  119 (6) 847-860
    CrossrefPubMedSearch in Google Scholar
  • 131 Hoffman J A, Giraudo E, Singh M et al.. Progressive vascular changes in a transgenic mouse model of squamous cell carcinoma.  Cancer Cell. 2003;  4 (5) 383-391
    CrossrefPubMedSearch in Google Scholar
  • 132 Sato M, Vaughan M B, Girard L et al.. Multiple oncogenic changes (K-RAS(V12), p53 knockdown, mutant EGFRs, p16 bypass, telomerase) are not sufficient to confer a full malignant phenotype on human bronchial epithelial cells.  Cancer Res. 2006;  66 (4) 2116-2128
    CrossrefPubMedSearch in Google Scholar
  • 133 Vaughan M B, Ramirez R D, Wright W E, Minna J D, Shay J W. A three-dimensional model of differentiation of immortalized human bronchial epithelial cells.  Differentiation. 2006;  74 (4) 141-148
    CrossrefPubMedSearch in Google Scholar

Brigitte N GompertsM.D. 

Department of Medicine, Division of Pulmonary and Critical Care Medicine, David Geffen School of Medicine at UCLA

10833 Le Conte Ave., A2-410 MDCC, Los Angeles, CA 90095

Email: bgomperts@mednet.ucla.edu